Gilles Nobecourt Overview
- Firm
- Andera Partners
- Primary Position
-
Partner, Andera...
- Primary Industry
-
Healthcare
- Active Board Seats
-
5
- Med. Deal Size
-
- Med. Valuation
-
Gilles Nobecourt General Information
Biography
Dr. Gilles Nobecourt serves as a Partner of the Andera Life Science team at Andera Partners. He also serves as a Board Administrator at Genkyotex. He serves as the Board Member at Crescendo Biologics. He served as a Board Member at Complexa. He also served as a Partner at Edmond de Rothschild Asset Management (Suisse). Previously, he joined the recruitment firm Russell Reynolds Associates as a consultant for pharmaceutical and biotechnology companies. Before that, he was Vice President of Global Operations of RPR Gencell, the San Francisco-based biotechnology division of Sanofi-aventis (previously Rhône Poulenc Rorer), and acted as Director of a commercial division in Mexico. Mr. Nobecourt began his career by serving in various government appointments in France, including Advisor to the Prime Minister, and Advisor to the Minister for Research and Industry. He serves as a Board member at Inotrem and GamaMabs. Mr. Nobecourt is a graduate of the Institut d 'Études Politiques in Paris, holds a master's degree in Applied Economics, and attended General Management training at the University of Stanford Global School of Business.
Contact Information
Address
- 2, place Rio de Janeiro
- 75008 Paris
- France
Gilles Nobecourt Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Andera Partners | Investor | Partner, Andera Life Science team | Paris, France | PE/Buyout |
Gilles Nobecourt Board Seats (5)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
Complix | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Diepenbeek, Belgium | |
Crescendo Biologics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Cambridge, United Kingdom | |
Evommune | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Palo Alto, CA | |
GamaMabs Pharma | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Toulouse, France | |
Inotrem | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Paris, France |
Gilles Nobecourt Lead Partner on Deals (21)
Gilles Nobecourt has been the lead partner on 21 deals. Their latest deal was with Crescendo Biologics, a drug discovery company. The deal was made for on 24-Jul-2023.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Crescendo Biologics | 24-Jul-2023 | Later Stage VC | Completed | Drug Discovery | Cambridge, United Kingdom | |
Evommune | 28-Jun-2023 | Completed | Drug Discovery | Palo Alto, CA | ||
Evommune | 29-Oct-2021 | Completed | Drug Discovery | Palo Alto, CA | ||
Inotrem | 11-Feb-2020 | Completed | Drug Discovery | Paris, France | ||
Crescendo Biologics | 30-Apr-2018 | Completed | Drug Discovery | Cambridge, United Kingdom | ||
Complexa | 26-Jul-2017 | Completed | Biotechnology | Berwyn, PA | ||
Pacifix | 27-Jan-2016 | Completed | Other Consumer Durables | Melbourne, Australia | ||
GamaMabs Pharma | 15-Dec-2015 | Completed | Drug Discovery | Toulouse, France | ||
Complix | 10-Apr-2015 | Later Stage VC (Series B) | Completed | Drug Discovery | Diepenbeek, Belgium | |
Genkyotex | 07-Jan-2015 | Later Stage VC (Series D) | Completed | Drug Discovery | Saint-Julien- en-Genevois, France |
Gilles Nobecourt Network (225)
Board Members (101)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Eric Viaud | Genkyotex | Self | Saint-Julien- en-Genevois, France | |
Martine George MD | GamaMabs Pharma | Self | Toulouse, France | |
Genkyotex | Vesalius Biocapital Partners | Saint-Julien- en-Genevois, France | ||
GamaMabs Pharma | Self | Toulouse, France | ||
Crescendo Biologics | Sofinnova Partners | Cambridge, United Kingdom |
Portfolio Executives (97)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Charles Hobley | Crescendo Biologics | Director, Finance | 24-Jul-2023 | Cambridge, United Kingdom |
Thomas Sandal | Crescendo Biologics | Vice President of Preclinical Development, Protein Engineering and Research and Development | 24-Jul-2023 | Cambridge, United Kingdom |
Crescendo Biologics | Vice President, Business Development | 24-Jul-2023 | Cambridge, United Kingdom | |
Crescendo Biologics | Chief Operating Officer | 24-Jul-2023 | Cambridge, United Kingdom | |
Crescendo Biologics | Chief Executive Officer, Chief Financial Officer, CBO & Board Member | 24-Jul-2023 | Cambridge, United Kingdom |
Fund Team Members (27)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Stephane Bergez | Andera Partners | Acto Mezzanine III | Paris, France |
Stephane Bergez | Acto Mezzanine | Acto Mezzanine III | Paris, France |
Andera Partners | Paris, France | ||
Andera Partners | Paris, France | ||
Edmond de Rothschild Private Equity | Luxembourg, Luxembourg |
Gilles Nobecourt Affiliated Funds (9)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
BioDiscovery 4 | Andera Partners | Venture - General | Closed | 2013 | ||||
Acto Mezzanine III | Andera Partners | Mezzanine | Closed | 2017 | ||||
BioDiscovery 3 | Andera Partners | Venture - General | Closed | 2008 | ||||
Winch Capital 3 | Andera Partners | Growth/Expansion | Closed | 2014 | ||||
Cabestan Capital Fund | Andera Partners | Buyout | Fully Invested | 2012 |
Gilles Nobecourt FAQs
-
Who is Gilles Nobecourt?
Dr. Gilles Nobecourt serves as a Partner of the Andera Life Science team at Andera Partners.
-
How much does Gilles Nobecourt typically invest?
Gilles Nobecourt's median deal size is
. -
What is Gilles Nobecourt’s main position?
Gilles Nobecourt’s primary position is Partner, Andera Life Science team.
-
What are the contact details for Gilles Nobecourt?
Gilles Nobecourt’s email address is g.
and his phone number is +33 01 . -
How many active board seats does Gilles Nobecourt hold?
Gilles Nobecourt holds 5 board seats including Complix, Crescendo Biologics, Evommune, GamaMabs Pharma, and Inotrem.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »